Baseline UK real-world study in ovarian cancer pre-PARPi published

  • A study was published recently on the real-world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors as a result of a collaboration between AstraZeneca and SVMPharma
  • The study, aside from providing a baseline for future evaluations to compare themselves to, produced survival data which complements randomised control trials (RCTs); for example, it described a shorter median overall survival for patients in the real-world than those reported in landmark RCTs
  • “[This study] will be an important benchmark for the future.” – Dr Ros Glasspool, Consultant Medical Oncologist at Beatson West of Scotland Cancer Centre

Click here for the article published in the International Journal of Gynaecological Cancer

SVMPharma’s chart note review provide the insights you need to meet your business needs. Click here to learn more

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

ref: APR2020LN002

Posted in Blogs.